Literature DB >> 12486185

Genetic dissociation of opiate tolerance and physical dependence in delta-opioid receptor-1 and preproenkephalin knock-out mice.

Joshua F Nitsche1, Alwin G P Schuller, Michael A King, Min Zengh, Gavril W Pasternak, John E Pintar.   

Abstract

Previous experiments have shown that mice lacking a functional delta-opioid receptor (DOR-1) gene do not develop analgesic tolerance to morphine. Here we report that mice lacking a functional gene for the endogenous ligand preproenkephalin (ppENK) show a similar tolerance deficit. In addition, we found that the DOR-1 and ppENK knock-outs as well as the NMDA receptor-deficient 129S6 inbred mouse strain, which also lacks tolerance, exhibit antagonist-induced opioid withdrawal. These data demonstrate that although signaling pathways involving ppENK, DOR, and NMDA receptor are necessary for the expression of morphine tolerance, other pathways independent of these factors can mediate physical dependence. Moreover, these studies illustrate that morphine tolerance can be genetically dissociated from physical dependence, and thus provide a genetic framework to assess more precisely the contribution of various cellular and molecular changes that accompany morphine administration to these processes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12486185      PMCID: PMC6758444     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  51 in total

1.  The prohormone proenkephalin possesses differential conformational features of subdomains revealed by rapid H-D exchange mass spectrometry.

Authors:  Weiya D Lu; Tong Liu; Sheng Li; Virgil L Woods; Vivian Hook
Journal:  Protein Sci       Date:  2012-01-04       Impact factor: 6.725

2.  How to design an opioid drug that causes reduced tolerance and dependence.

Authors:  Amy Chang Berger; Jennifer L Whistler
Journal:  Ann Neurol       Date:  2010-05       Impact factor: 10.422

3.  Differential involvement of endogenous opioids in sucrose consumption and food reinforcement.

Authors:  Michael D Hayward; Alexandra Schaich-Borg; John E Pintar; Malcolm J Low
Journal:  Pharmacol Biochem Behav       Date:  2006-12-12       Impact factor: 3.533

4.  Modified 'Joyce model' of opioid dependence/withdrawal.

Authors:  Robert B Raffa; Ronald J Tallarida
Journal:  Eur J Pharmacol       Date:  2006-09-16       Impact factor: 4.432

5.  Naltrindole inhibits human multiple myeloma cell proliferation in vitro and in a murine xenograft model in vivo.

Authors:  Jyoti Joshi Mundra; Alexandra Terskiy; Richard D Howells
Journal:  J Pharmacol Exp Ther       Date:  2012-04-26       Impact factor: 4.030

Review 6.  Candidate gene polymorphisms predicting individual sensitivity to opioids.

Authors:  Shinya Kasai; Masakazu Hayashida; Ichiro Sora; Kazutaka Ikeda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-11-13       Impact factor: 3.000

7.  Differential involvement of enkephalins in analgesic tolerance, locomotor sensitization, and conditioned place preference induced by morphine.

Authors:  Paul Marquez; Ramkumarie Baliram; Nagaraju Gajawada; Theodore C Friedman; Kabirullah Lutfy
Journal:  Behav Neurosci       Date:  2006-02       Impact factor: 1.912

8.  A new opioid designed multiple ligand derived from the micro opioid agonist endomorphin-2 and the delta opioid antagonist pharmacophore Dmt-Tic.

Authors:  Severo Salvadori; Claudio Trapella; Stella Fiorini; Lucia Negri; Roberta Lattanzi; Sharon D Bryant; Yunden Jinsmaa; Lawrence H Lazarus; Gianfranco Balboni
Journal:  Bioorg Med Chem       Date:  2007-08-29       Impact factor: 3.641

9.  The MOR-1 opioid receptor regulates glucose homeostasis by modulating insulin secretion.

Authors:  Ting Wen; Bonnie Peng; John E Pintar
Journal:  Mol Endocrinol       Date:  2009-02-12

10.  Tuned-Affinity Bivalent Ligands for the Characterization of Opioid Receptor Heteromers.

Authors:  Jessica H Harvey; Darcie H Long; Pamela M England; Jennifer L Whistler
Journal:  ACS Med Chem Lett       Date:  2012-08-09       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.